4D Molecular Therapeutics, Inc. (FDMT) Total liabilities 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) total liabilities at each fiscal year-end, per SEC filings.
$61.0MFY2025 · since FY2019: $28.2M → $61.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $61.0M | +22.6% |
| FY2024 | $49.8M | +55.3% |
| FY2023 | $32.1M | +5.1% |
| FY2022 | $30.5M | -11.3% |
| FY2021 | $34.4M | +7.6% |
| FY2020 | $31.9M | +13.2% |
| FY2019 | $28.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net incomeFDMT Net marginFDMT Gross profitFDMT Gross marginFDMT Operating incomeFDMT Operating marginFDMT Operating cash flowFDMT Free cash flowFDMT Capital expendituresFDMT Return on equityFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Shareholders’ equityFDMT overview →